EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/01/2025
Voltar para busca
Dado oficial do USPTO
ENTOS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
08/01/2025
Tipo de marca
Mista
Classes Nice
40, 42, 44
Data de depósito
14/09/2022
Data de registro
19/11/2024
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/11/2024
Última transação
08/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Primeiro uso
2011-04-00
Primeiro uso no comércio
23/01/2018
Código do desenho
3
Tipo de titular
03
Localização do titular
EDMONTON, AB, CA
Examinador
HENRY,NAKIA D
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the word "entos" and to the right three concentric rings of circles with the circles increasing in diameter from the inner ring to the outer ring.
Titulares e representantes
Titulares
Entos Pharmaceuticals Inc.
Entos Pharmaceuticals Inc.
Representantes
Theodore R. Remaklus Thompson Hine LLP
Classificação técnica
Classes Nice
Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Custom manufacture of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies
Classe 42
Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific researchpharmaceutical researchmedical researchtechnical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticalstherapeutic agents and medical devices; research and product development in the field of human vaccinesrecombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates
Classe 44
Medical therapy servicesnamely gene therapy services; medical analysis servicesnamely RNA or DNA analysis for virus diagnosis and prognosis; medical information servicesproviding information to physicianshealthcare professionals and patients on the topics of health issues that can be treated with vaccinesrecombinant proteins and antibodiesdiagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; on-line information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of health issues that can be treated with vaccinesrecombinant proteins and antibodiesdiagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; genetic testing for medical purpose
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/01/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/01/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/01/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/01/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/01/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
19/11/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/09/2024
PUBO
PUBLISHED FOR OPPOSITION
03/09/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/08/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/07/2024
DPCC
DIVISIONAL PROCESSING COMPLETE
25/06/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/06/2024
ALIE
ASSIGNED TO LIE
06/04/2024
DRRR
DIVISIONAL REQUEST RECEIVED
16/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/11/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
16/11/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
27/09/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
27/09/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/06/2023
GNRT
NON-FINAL ACTION E-MAILED
27/06/2023
CNRT
NON-FINAL ACTION WRITTEN
27/06/2023
DOCK
ASSIGNED TO EXAMINER
26/06/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
30/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/09/2022
NWAP
NEW APPLICATION ENTERED
17/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ENTOS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.